ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

Wu Yi Long*; Sequist Lecia V; Hu Cheng Ping; Feng Jifeng; Lu Shun; Huang Yunchao; Li Wei; Hou Mei; Schuler Martin; Mok Tony; Yamamoto Nobuyuki; O'Byrne Kenneth; Hirsh Vera; Gibson Neil; Massey Dan; Kim Miyoung; Yang James Chih Hsin*广东省人民医院; 吉林大学; 上海交通大学; 昆明医学院; 四川大学; 中南大学; 香港中文大学; 2; 1
British Journal of Cancer2017-1-17DOI: 10.1038/bjc.2016.420
5阅读
引用收藏
分享

摘要

Background: In the Phase III LUX-Lung 3/6 (LL3/LL6) trials in epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma patients, we evaluated feasibility of EGFR mutation detection using circulating cell-free DNA (cfDNA) and prognostic and predictive utility of cfDNA positivity (cfDNA+). <br>Methods: Paired tumour and blood samples were prospectively collected from randomised patients. Mutations were detected using cfDNA from serum (LL3) or plasma (LL6) by a validated allele-specific quantitative real-time PCR kit. <br>Results: EGFR mutation detection rates in cfDNA were 28.6% (serum) and 60.5% (plasma). Mutation detection in blood was associated with advanced disease characteristics, including higher performance score, number of metastatic sites and bone/liver metastases, and poorer prognosis. In patients with common EGFR mutations, afatinib improved progression-free survival vs chemotherapy in cfDNA+ (LL3: HR, 0.35; P = 0.0009; LL6: HR, 0.25; P < 0.0001) and cfDNA- (LL3: HR, 0.46; P < 0.0001; LL6: HR, 0.12; P < 0.0001) cohorts. A trend towards overall survival benefit with afatinib was observed in cfDNA+ patients. <br>Conclusions: Plasma cfDNA is a promising alternative to biopsy for EGFR testing. Detectable mutation in blood was associated with more advanced disease and poorer prognosis. Afatinib improved outcomes in EGFR mutation-positive patients regardless of blood mutation status.

学科与关键词

关键词
afatinibcirculating cell-free DNAErbB family blockerEGFR mutationnon-small cell lung cancer
相关
加载中…
  • Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
    Wang, Zhijie; Cheng, Ying; An, Tongtong; Gao, Hongjun; Wang, Kai; Zhou, Qing; Hu, Yanping; Song, Yong; Ding, Cuimin; Peng, Feng; Liang, Li; Hu, Yi; Huang, Cheng; Zhou, Caicun; Shi, Yuankai; Zhang, Li; Ye, Xin; Zhang, Meizhuo; Chuai, Shaokun; Zhu, Guanshan; Hu, Jin; Wu, Yi-Long*; Wang, Jie*Lancet Respir Med, 2018, 6(9): 681-690.
  • EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
    Ianza, Anna*; Di Chicco, A.; Biagi, C.; Giudici, F.; Dicorato, A.; Guglielmi, A.; Variola, F.; Tomasi, S.; Roviello, G.; Generali, D.; Zanconati, F.Journal of Cancer Research and Clinical Oncology.
  • Circulating DNA addresses cancer monitoring in non small cell lung cancer patients for detection and capturing the dynamic changes of the disease
    Wei Z; Shah N; Deng C; Xiao X; Zhong T; Li X*SpringerPlus, 2016, 5(1).
查看全部 →

发表信息

论文状态
公开发表
期刊
British Journal of Cancer
发表日期
2017-01-17
卷期
第 116 卷, 第 2 期
页码
175-185
DOI
10.1038/bjc.2016.420
语言
ENGLISH
期刊等级
Q1
成果收录
SCI
资助标注
Boehringer Ingelheim; GeoMed; Ashfield business; UDG Healthcare plc

作者

  • W

    Wu Yi Long (通讯) (第一作者)

    guangdong gen hosp · 2

  • S

    Sequist Lecia V

查看全部 17 位作者收起作者
  • H

    Hu Cheng Ping

    cent s univ

  • F

    Feng Jifeng

  • L

    Lu Shun

    shanghai jiao tong univ

  • H

    Huang Yunchao

    kunming med univ

  • L

    Li Wei

    1

  • H

    Hou Mei

    1

  • S

    Schuler Martin

  • M

    Mok Tony

    chinese univ hong kong

  • Y

    Yamamoto Nobuyuki

    1

  • O

    O&#39;Byrne Kenneth

  • H

    Hirsh Vera

  • G

    Gibson Neil

  • M

    Massey Dan

  • K

    Kim Miyoung

  • Y

    Yang James Chih Hsin (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417